In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies.

00:35 - Guest Introduction

01:10 - SELECT Results Overview

04:25 - Next Steps for Research

07:15 - Mechanism of Action for CV Benefit

09:00 - FLOW Trial Implications

11:25 - Impact on Access

15:00 - Future of Incretin Therapies

21:45 - Predicting the Next 5-10 Years for Semaglutide